NF-kappa-B inhibitor beta (NFKBIB)

NF-kappa-B inhibitor beta is a cytoplasmic regulatory protein encoded by the NFKBIB gene that belongs to the NF-kappa-B inhibitor family[1][3][4][5][8]. Its primary role is to suppress the activity of the NF-kappa-B transcription factor complex by sequestering it in the cytoplasm, preventing translocation to the nucleus and subsequent DNA binding. Upon cellular stimulation, NFKBIB is phosphorylated by I-kappa-B kinases, leading to its degradation via the ubiquitin-proteasome pathway and freeing NF-kappa-B to initiate gene transcription, crucial for immune and inflammatory responses. NFKBIB's slower degradation, compared to other family members, provides nuanced control over NF-kappa-B signaling[1][4][8]. Disruption of its function is associated with immune deficiency and abnormal inflammatory signaling, highlighting its importance in disease regulation[3][4][6][7].

Other names

IKBBIkappaBbetaI-kappa-B-betaIkB-betanuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, betaTRIP9TR-interacting protein 9NF-kappa-BIBIkB-BNF-kappa-B inhibitor beta (multiple formats)Thyroid receptor-interacting protein 9

Drugs targeting the NF-kappa-B pathway may act by preventing the phosphorylation or degradation of NFKBIB, stabilizing its inhibitory complex with NF-kappa-B and keeping the transcription factor inactive in the cytoplasm. Other mechanisms include nuclear retention of IkappaB by inhibiting nuclear export proteins (e.g., XPO1 inhibitors).